Abstract: Point estimation is particularly important in predicting weight loss in individuals or small groups. In this analysis, a new health response function is based on a model of human response over time to estimate long-term health outcomes from a change point in short-term linear regression. This important estimation capability is addressed for small groups and single-subject designs in pilot studies for clinical trials, medical and therapeutic clinical practice. These estimations are based on a change point given by parameters derived from short-term participant data in ordinary least squares (OLS) regression. The development of the change point in initial OLS data and the point estimations are given in a new semiparametric ratio estimator (SPRE) model. The new response function is taken as a ratio of two-parameter Weibull distributions times a prior outcome value that steps estimated outcomes forward in time, where the shape and scale parameters are estimated at the change point. The Weibull distributions used in this ratio are derived from a Kelvin model in mechanics taken here to represent human beings. A distinct feature of the SPRE model in this article is that initial treatment response for a small group or a single subject is reflected in long-term response to treatment. This model is applied to weight loss in obesity in a secondary analysis of data from a classic weight loss study, which has been selected due to the dramatic increase in obesity in the United States over the past 20 years. A very small relative error of estimated to test data is shown for obesity treatment with the weight loss medication phentermine or placebo for the test dataset. An application of SPRE in clinical medicine or occupational therapy is to estimate long-term weight loss for a single subject or a small group near the beginning of treatment.
Introduction
Point estimation is particularly important in predicting weight loss in individuals or small groups. In this analysis, G k ; τðtÞ is a new response function based on a model of human response over time to estimate long-term health outcomes from a change point in short-term linear regression. The statistical problem considered here can be stated simply. The statistical problem stated here can be stated simply: having initial quasi-linear data from participant's primary or secondary datasets, determine the change point from a backwards' stepwise regression model. Then, using a ratio of the function G k ; τðtÞ, times, the prior estimated outcome, determine new point estimates from the change point to the time where the ratio becomes 1.00. This indicates participant(s) stability or no further change. These point estimations taken from the change point are a new semiparametric ratio estimator (SPRE), using mean response and single-subject design for clinical medicine, therapy in the health sciences or pilot studies for phase I clinical trials.
Why are we interested in predicting health outcomes for single subjects or small groups? The motivation in this article comes from occupational therapy in health sciences where efficacy and duration of treatment has not been able to be satisfactorily statistically determined. Even single-subject experimental studies are often discarded, because it is thought that they cannot yield valid results according to Thompson [1] . The importance to therapy and clinical medicine cannot be overstated, particularly where the medical model emphasizes the systematic use of information about an individual that is broader than genomics to enable a tailored approach to prevention and care. This problem is particular to clinical medicine and therapy in health science where a small number of 5-10 participants in groups, for example, are too few for the results to be analyzed using classical statistics that depend upon larger numbers for statistical significance.
A secondary analysis is performed on data from a classic double-blind obesity study by Munro et al. [2] and analyzed by Bray [3] , which provides a well-documented trial to determine the efficiency and accuracy of weight loss estimations using the new SPRE model for the small group assuming that weight loss is represented by the mean at any point in time.
The collected data are for 17 women treated with the phentermine and 22 women treated with placebo, whose mean weight change was noted every 4 weeks from the start of the trial to the conclusion at 36 weeks. This secondary analysis compares predicted weight loss starting from a change point derived from initial data in the first 8.0 weeks for participants treated with phentermine and in the first 4.6 weeks for participants treated with placebo. Test data compare very well to point estimations of continuous phentermine and placebo. The Munro et al. and Bray analyses are chosen to illustrate the use of SPRE, because prevalence and incidence of obesity have public health consequences as precursors for diabetes, congestive heart disease, high blood pressure, stroke, among others [4] .
The model

Assumptions for the data using the SPRE model
The first assumption is that 13-20 data points in the primary trial follows an initial quasi-linear form that can be analyzed by ordinary least squares (OLS) to develop a change point. This is true for a single subject or a small group where the mean indicates the response to treatment. The second assumption is that the outcome values are ordered data. If the data are not approximately linear, then transforms are used to linearize the data, and if both axes are transformed, then values on the time axis are ordered together with the ordered outcome data. The approximate linearity of the initial data is based on a linear relationship implicit in the solution of a convolution integral on which the predictive health response function is based [5] . A third assumption is that a change point can be determined from initial data before an arbitrary cutoff in time or treatment numbers. A fourth assumption is that long-term data outcomes can be given from a change point using a ratio of G k ; τðtÞ times the prior outcome point estimation.
Identify the change point in the initial patient least squares data
The equations for OLS regression analyses are given by Berk [6] and Weisberg [7] where the weight loss data consists of n observations. Each observation includes the scalar outcomes response y i and a vector of predictors (regressors) x i . In this linear regression model the response variable is a linear function of the regressors:
where β is a p Â 1 vector of unknown parameters; ε i s are unobserved scalar random variables (errors) which account for the discrepancy between the actually observed responses y i and the "predicted outcomes" x 0 i β; and 0 denotes matrix transpose so that x 0 β is the dot product between the vectors x and β. There are several different frameworks in which the linear regression model can be cast in order to make the OLS technique applicable. The choice of the applicable framework depends mostly on the nature of data that is observational in this article. Then, the regressors are random variables, and the regressors' x i is random and sampled together with the y i s from this weight loss population. Suppose b is a "candidate" value for the parameter β. The value of b that minimizes is sðbÞ called the OLS estimator for β in eq. (1) where
Generally speaking, change-point regression is a regression problem in which the expected value of the dependent variable or response is assumed to have a different functional form in several neighborhoods of the explanatory variable space according to Khodadadi and Asgharian [8] . In the SPRE model, the determination of the change point is a structural change that shows the dynamic nature of the changes for weight loss. A novel estimation procedure using a backward-stepwise regression comparatively determines the highest or lowest F statistic for each regression model reduced by reasonably even increments of time or the even number of treatment sessions. The time at the change point is the location of the initial G k ; τðtÞ ratio predictions for long-term estimates, which produces a gradually changing predictive model. The region of analytical interest for the backward-stepwise elimination method is shown in Figure 1 using 12 weeks of initial weight loss for Munro et al. and the Bray [3] obesity analysis.
The highest or lowest value of the F statistic in this article, for the area as shown in Figure 1 , is derived by equations relying on x and y and for this derivation follow the relation given by Wu [9] for F ¼ t Miller et al. [10] , and inflection between the 4th and 5th test data points from a recent pilot study for BMI by Brown et al. [11] . The derivation for the least squares estimate of OLS regression is given as:
And:
And: t ¼β
After algebraic manipulation, the highest or lowest F statistic is determined by
The results are given in Table 1 for the weight loss treatment with phentermine. These results were computed by the R Development Core Team [12] , R Commander by Fox [13] , and using R Commander [15] . In R Commander, a linear model was used to include the ANOVA results, particularly the F statistic. It should be noted that in this SPRE model, the F statistic is determined comparatively from the regression analyses, where the p value is used to determine statistical significance of the regression analysis to that point. The resulting change point, of the highest or lowest F statistic computed, is then denoted by the value of time, or treatment session number, together with the measured outcome in the dataset. Determining the highest or lowest F statistic using a nested equations model according to Berk [4] and Faraway [16] produces F statistics derived from evaluation of the y relationships alone. In this case, the value of the F statistic continuously decreases from low to high values of say 12 weeks for this dataset. Another approach taken from Wu [7] , where the highest or lowest F statistic is derived by pooled estimates that depend only upon x, the value of the F statistic continuously increases from low to high values of 12 weeks.
It can be seen from the analyses in Table 1 that the highest F statistic is at time ¼ 8.0 weeks from the backward-stepwise elimination method, including the variables x (time) and y (outcome), as given in eq. (6). Each dataset, starting at an assumed full model at 12 weeks, is analyzed to determine R 2 and the F statistic.
Then, the next dataset is analyzed from 10.5 weeks down to 3.4 weeks. In weight loss therapy, the treatment should be carried out past the first highest F statistic (a first mode) to be sure that all relevant modes, such as a second mode of response, have been recorded. As shown in Figure 1 , there is one measured high value of the "F " statistic for both continuous treatments at 8.0 weeks and placebo at 4.6 weeks, where the data has normally distributed residuals fitted against time. These points are shown in Figure 1 with lines pointing to the relevant datasets. It should be noted that the placebo outcomes also have a minor inflection point, in this case between the third and fourth data points. Therefore, this inflection is taken to be a function of weight loss and not of the type of treatment from continuous phentermine to placebo in this analysis.
In this article, a change point is defined as the time ¼ τ for the highest F statistic, located in this dataset at 8.0 weeks, where the weight loss outcomes with respect to time are no longer linear [17] [18] [19] . In medical models of response to treatment, the change point is the data point at which the character of the regression changes, in general, from linear to the shape of an exponential or the Weibull cumulative distribution [18] . Two examples of this character of the regression are shown in this weight loss study and in a prospective pilot program on childhood obesity [11] . More detailed presentation of model results is given in a study for treatment of adults with developmental disabilities by Link et al. [20] .
Derivation of the predictive parameter G k ; τðtÞ ratio
The time at the change point determines the location of the initial ratio predictions for long-term estimates from the least squares set of random pairs fðY t ; X t Þg t2T .
The predictive function is derived from a Kelvin model in continuum mechanics [5] chosen to model human response to disease as given by Weissman-Miller [18] . The Kelvin model is shown in Aklonis and MacKnight [21] , and the generalized Kelvin-Voight model is derived in Mills [22] . The original Kelvin model predicts the relaxation, or change point, of complex materials and can be used to model the human body's bones and sinews together with the viscous properties such as blood and water. The transformed model is given here as a cumulative Weibull distribution, rather than an exponential distribution with the superscript "k" assumed to be 1.00. This new predictive function is given as G k ; τðtÞ to determine the shape of the predictive curve, where G k is the response function of the human body to treatment expressed with the shape parameter "k" and τðtÞ that are measures of time:
This equation is used in the SPRE model specifically, because it includes G k ; τðtÞ as a function of time, and a prior in the form of τ that has been derived as time at the change point in the SPRE model. Finally, the right-hand side of this equation is widely used in survival analysis together with the cumulative exponential distribution of a survival function when residuals are not distributed normally [23] and for time-to-eventdata [24] . To derive G k ; τðtÞ as a ratio, an assumption is made that a statistical function ΨðtÞ relates θ t and τðtÞ, outcomes and a function of time, on the initial OLS data regression line and is a bivariate function. These equations, given here as τðtÞ ¼ τ Â G k ; τðtÞ , and θ t ¼ θ τ Â G k ; τðtÞ, are evaluated on G k ; τðtÞ for θ t which is a population parameter at the change point in the OLS regression. The cumulative Weibull distribution in eq. (7) is given as a ratio in Weissman-Berman [25] , Weissman-Miller [18] , and Weissman-Miller et al. [10] . The outcomes beyond τ are point estimates and given asθ t .
At time greater than τ when t iþ1 is the increased value of time for the point estimates, t i is the prior time and the ratio is multiplied by the prior outcome θ t i to determine the new point estimate:
In general,G k ; τðt iAE1 Þ depends upon the value of the ordered outcomes. In the Weibull distribution,k is the predicted shape parameter and τ is the scale parameter, both derived from the initial least squares data regression line at the change point. Then, a ratio of this distribution varies with the value of time, and the right-hand side of eq. (8) steps the point estimations of the outcomes forward in time. The point estimates continue either until an assumed trial cutoff or until the ratio R ¼ 1:00 is determined for no further weight loss. These point estimations of weight loss are given as approximately evenly spaced time-dependent treatment outcomes.
Derivation of the Weibull distribution parameters
The parameter of health outcomes, in this case, is given by θ, where the estimatorθ t is a finite-dimensional semiparametric ratio of the Weibull cumulative distributions times the prior point estimate denoted as θ t i . This new response function G k ; τðtÞ is a special case of a two-parameter Weibull where both the shape and the scale parameter are estimated from the initial least squares regression. A one-parameter Weibull distribution reduces model uncertainty and potential bias of the shape parameter "k" estimated from the slope of the OLS regression line, when τ is given from the change point and the remaining variable is time [26] . It is shown by Meng [27] that the absolute bias ratio (ABR) of a single ratio estimator r s will be typically small in practice even with moderate sample size.
Given that the shape parameter is estimated and the scale parameter is given at τ from a least squares regression (with an R 2 equal to or higher than 0.45 for the health professions) and the outcome is the ratio times the prior value of the outcome, then the point estimations initiated at some distance from the origin are a shifted Weibull distribution by assumption and the results are point estimations or predictions. The scale parameter τ is defined as the time associated with the highest F statistic, in this dataset as 8.0 weeks for treatment with phentermine and 4.6 weeks for placebo. The shape parameter k is given from the slope of the initial least squares regression line, wherek can be determined from the Weibull distribution as given in Freund and Walpole [28] , Rice [29] , and Tobias and Trindade [30] . The estimated shape parameterk is determined from the CDF of the Weibull distribution times τðtÞ, the value of x at τðtÞ, when it is set equal to the slopeβ 1 of the least squares linear regression from 0 to τ as follows:
In practice, the calculation of the slope should also be taken as the absolute value, and τðtÞ ¼ t (at the change point). In this article,k ¼ 2:757 at 8.0 weeks (for the highest "F" statistic) for weight loss due to treatment with phentermine andk ¼ 1:616 for placebo.
Point estimate properties
The point estimate given by the ratio of the response function times the prior outcome in the SPRE model is unbiased at both time ¼ τ and when the Weibull ratio distributions R ¼ 1.00 from eq. (8) . The point estimation for the outcomeθ t at τ equals the data outcome at τ. When the ratio ¼ 1.00:
The sequential predictions ofθ t are bounded by unbiased estimators at time ¼ τ and when the ratio ¼ 1.00,
At the change point and when the ratio R ¼ 1:00, the values of the statisticθ t on the real axis estimate the population parameter θ [28] . Furthermore, this estimator is consistent at the beginning and end points of analysis, because it is unbiased at the change point and when the ratio R ¼ 1:00 as shown in eq. (10) . Therefore, this estimator is consistent at the upper and lower bounds, and the ABR of this SPRE ratio will be typically small in practice as given in Meng [27] . The ratio estimator is insensitive to small departures from the results of the statistical assumptions and methodology used to derive the prior k and τ. Therefore, this ratio estimator is also robust.
Using this model, repeated measures may underestimate or overestimate the standard error of a regression coefficient computed from an OLS [30, 31] . However, as long as circularity is maintained, when random errors are random, the F statistic derived from both x and y as given in eq. (6) will not be affected. At τ, the parameter θ τ is derived from the initial sample data, while the predictive parameterθ t indicates sequential predictions for that single-subject or small-group design. The mean μ is the normal distribution parameter for the response of a small group, given as parameter θ.
Results
The point estimates adapted from long-term data from an analysis given by Munro et al. [2] and subsequently by Bray [3] , comparing continuous administration of phentermine with placebo are given in Table 2 .
In this analysis, the residuals at the final change points τ at 8.0 weeks were random and normal. Weight loss predictions are computed for treatment with phentermine and placebo, and the results for both are graphed in Figure 2 . The SPRE model predicts the phentermine therapy weight loss treatment with a 1.1% relative error to measured data at 36 weeks for this study. The results for placebo have a relative error to measured data of 5.4% at 36 weeks. The relative error of point estimates to the secondary data is excellent for treatment (at 36 weeks) and placebo (at 36 weeks). The response function ratio predictions from each change point show clearly that there is significantly greater weight loss for patients treated with phentermine than for patients treated with placebo. The SPRE analysis confirms the same result measured in the clinical trial.
Discussion
The predictions in this article are based on the calculation of a change point at 8.0 weeks for phentermine and 4.6 weeks for placebo from a least squares regression of initial data. The point estimates predict weight loss on a 2-week interval over time after 8.0 weeks for phentermine and after 4.6 weeks for placebo, and they are based on the values of previous events. For this reason, this model is especially useful in predicting weight loss in obesity and weight control programs. Furthermore, predicting the numbers of treatments until the participant becomes stable reduces waste and controls costs in health care.
Conclusions
The relative error of predicted to test data is very good for the long-term test data for weight loss therapy as shown in Figure 2 . This point estimator in eq. (7) taken as a ratio from the SPRE model in eq. (8) has been shown to be unbiased at the upper and lower bounds at the change point and when the ratio R ¼ 1:00 and has also been shown to be consistent at the upper and lower bounds of prediction and robust for single subjects or a small group. Furthermore, the ABR of this SPRE ratio will be typically small in practice as given in Meng [27] , whether the model is for a small group or the long-term predicted outcomes for a single subject. If the small group has 5-10 participants, then it is proposed that inferences may be made to a larger population provided that the p value at the change point is 0:05. 
Point estimation in weight loss programs and phentermine
There are several other considerations to use the SPRE model specifically to estimate future weight loss. Any decision to attempt a weight reduction program must also consider the patient's readiness to commit to change [31] . One may use the SPRE model to predict weight loss. If patients are encouraged to look at their own possible weight loss, time, and personal effort, they may be better able to attain their own weight loss goals. Therefore, the response function ratio times the prior outcome estimation curve should be computed early in the weight loss treatment program, so that it can be used as a motivating force, for example, in programs addressing childhood obesity monitored in a school setting by an occupational therapist, as well as for clinical medical monitoring and for estimating medical and weight loss improvement.
